- Company
- Daewoong signs an export contract for Fexuprazan
- by Kim, Jin-Gu Aug 19, 2020 06:28am
- Daewoong announced on the 14th that it has signed an export contract with EMS in Brazil for the P-CAB-affiliated gastric secretion inhibitor Fexuprazan. The contract amount is $72.58 million. EMS will be responsible for the local approval of Fexuprazan in Brazil. The export is expected to proceed in earnest after obtaining permission to B
- Policy
- No more approval on all appetite suppressants
- by Lee, Tak-Sun Aug 19, 2020 06:28am
- New approval on appetite suppressant amfepramone, also known as diethylpropion hydrochloride, and mazindol drugs would be restricted. These substances were added to the list of restricted approval substance due to the risk of abusing narcotics for medical purposes. Now, the list of restricted narcotic drugs includes amfepramone, mazindol
- Policy
- Vaccine by Novavax, produced by SK Bioscience
- by Kim, Jung-Ju Aug 19, 2020 06:27am
- The government has signed a letter of intent (LOI) for cooperation in domestic production and supply in order to smoothly supply the vaccine developed overseas for COVID-19. The domestic supply chain is SK Bioscience, which has joined the production of AstraZeneca products. The MOHW (Minister Park Neung Hoo) at SK Bioscience Research Insti
- Policy
- Development of generic for Pelubi is active
- by Lee, Tak-Sun Aug 18, 2020 06:03am
- Daewon Pharm’s anti-inflammatory generics for Pelubi, which recorded an outpatient prescription of &8361;28.9 billion last year, is actively developing. In July, the first application for permission of generic for Pelubi was received, and nine bioequivalence test plans were approved this year. Generic companies are now developing not onl
- Company
- “Safe, effective and convenient Zejula for ‘all-comers'"
- by Eo, Yun-Ho Aug 18, 2020 06:03am
- Different drugs in a same class can have different indications. It could be a development strategy by pharmaceutical companies or a Columbus’ egg. But clearly, the respective companies would try to appeal for different indications in different prescription area and relevant benefit proven from safety and efficacy data. Two poly ADP-
- Company
- Competition of Humira biosimilars intensifies
- by Kim, Jin-Gu Aug 18, 2020 06:03am
- Celltrion and LG Chem compete in earnest in the biosimilar market of Humira (Adalimumab). Both companies have completed phase III clinical trials and are currently working on preliminary work to apply for product approval. If Samsung Bioepis, which has already obtained approval for the product, releases its product early next year, competi
- Policy
- Zolgensma was added to target diseases
- by Lee, Tak-Sun Aug 18, 2020 06:02am
- The minutes of the Central Pharmaceutical Affairs Review Committee were released in connection with the expansion of the target age of the expensive drug 'Zolgensma' of &8361;2.5 billion, and it was revealed that the target disease was added on the 3rd. The committee presented a negative opinion on the expansion of the age group, but Orph
- Company
- Ezetimibe combo drug market grows steeply amid COVID-19
- by Chon, Seung-Hyun Aug 18, 2020 06:02am
- In the dyslipidemia treatment market, the volume of ezetimibe combination drug prescription is expanding rapidly. Preference in prescribing ezetimibe combined with rosuvastatin or atorvasutatin is growing fast. Hanmi Pharmaceutical’s Rosuzet and MSD’s Atozet seem to be leading the steep increase in the use of ezetimibe combination therapy.
- Company
- The safety of Statin therapy has been proven
- by Nho, Byung Chul Aug 14, 2020 03:17pm
- As the Cerebral Cardiovascular Disease Control Act was revised in April, dyslipidemia was included in the range of cerebrovascular diseases under the current law, along with hypertension and diabetes. It is explained that the severity and risk of dyslipidemia have been recognized at the national level and the willingness to support is indicat
- Company
- Zejula, re-challenges 'all comer' for ovarian cancer
- by Eo, Yun-Ho Aug 14, 2020 06:23am
- The anticancer drug 'Zejula' once again challenges 'all comer' insurance benefit through the first line maintenance therapy for ovarian cancer. According to related industries, Takeda Korea recently introduced epithelial ovarian cancer or fallopian tubes that showed a complete or partial response to primary platinum-based chemotherapy rega
